NEW BLOG POST! Check out the latest edition of our 'RARE' blog series by our Principal Consultant, Laura Hulley. On this episode of RARE, Laura welcomed Tomas Baldwin, Co-Founder and CEO of the UCL-spin out Guilford Street Laboratories. A company that was created to advance the state of diagnostics in healthcare, particularly for those suffering with rare, cardiac and neurodegenerative diseases. Read the blog and watch the full interview through the link below 👇 https://lnkd.in/evGFMZqR #RareDiseases #RareDiseaseAwareness #Blog
SciPro’s Post
More Relevant Posts
-
Are you, too, heading for AD/PD 2024 in Lisbon, Portugal? 👋 Come meet our #teamfujirebio with experts from Marketing, Sales and R&D (see comments 👇 for details) who are eager to discuss the latest within the field of neurodegenerative disease testing - find us at booth 6 👉 https://lnkd.in/eMZcHtum #ADPD #neurodegeneration #alzheimersdisease #parkinsonsdisease
To view or add a comment, sign in
-
We look forward to participating in the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston! Learn more about the science we are advancing in Alzheimer’s research: https://ow.ly/W52p50PZRmS #AlzheimersDisease | #CTAD23 | #AlzheimersResearch
To view or add a comment, sign in
-
-
Evaluating disease-modifying therapies for Parkinson's disease (PD) requires exploring new methods to assess disease progression in the early stages of the disease. In the past few years, Modus Outcomes has contributed to several research collaborations on this stimulating question. Our latest research in this area was presented last week at International Congress of the International Parkinson and Movement Disorder Society in Copenhagen. In an analysis of data from the Parkinson’s Progression Markers Initiative (PPMI) de Novo PD cohort, we showed how a subset of 15 items from the part III (motor sign severity) of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPRS) can be repurposed to create a promising measure of bradykinesia and rigidity, which are typical signs of early-stage PD. Read the abstract here: https://rb.gy/zv9o1 For more information on this research or on how Modus Outcomes can help with exploring novel endpoints for use in the development of therapies in atypical settings, please contact Tara Willoughby, Business Development Coordinator, Modus Outcomes (a division of THREAD). #PCOR #PatientVoice #ParkinsonsDisease #MovementDisorders #MDSCongress
To view or add a comment, sign in
-
-
I am thrilled to announce that my research paper titled "Utilizing Machine Learning Approaches for Cardiovascular Disease Forecasting" has been published by IEEE! Heart disease remains the leading cause of death worldwide, and early detection is crucial for effective treatment. In our study, we explored various machine learning techniques to predict the probability of individuals developing coronary heart disease within ten years. This research aims to aid healthcare providers in making more precise, trustworthy, and swift diagnoses, ultimately contributing to better patient outcomes. For those interested in a deeper dive into our methodology and results, you can read the full paper here: https://lnkd.in/g-kzk72q #Research #MachineLearning #CardiovascularDisease #HealthcareInnovation #DataScience #AcademicPublication #IEEE
Utilizing Machine Learning Approaches for Cardiovascular Disease Forecasting
ieeexplore.ieee.org
To view or add a comment, sign in
-
Registries are powerful tools for conducting observational studies of disease with impact on public health surveillance, research, and intervention, and inform and engage policymakers. Frank Jessen, one of our founding Board members, shared at the EADC (European Alzheimer's Disease Consortium) annual meeting how InRAD may impact clinical management, foster large-scale collaborations, and enable global studies. Join us in accelerating Alzheimer's research! https://lnkd.in/gGDTvs6i #InRAD #AlzheimersResearch #GlobalImpact #EADC #RealWorldData #AlzheimersRegistry
We were delighted to introduce InRAD, an international, practice-based registry for Alzheimer's Disease and other dementias at the EADC (European Alzheimer's Disease Consortium) annual meeting yesterday. One of our founding Board members, Frank Jessen, explained how InRAD can help address pressing questions about the clinical management of Alzheimer's disease, enable large study collaborations with a common minimum data set and facilitate a wide range of sub-studies on a global scale. Click here to find out more about InRAD and join our effort to accelerate progress in Alzheimer's practice-based research: https://lnkd.in/gGDTvs6i #InRAD #AlzheimersResearch #GlobalImpact #EADC #RealWorldData #AlzheimersRegistry
To view or add a comment, sign in
-
-
Thanks MIT School of Engineering for covering my research!
Yuzhe Yang is a Takeda Fellow in MIT EECS who is developing an AI-based diagnosis model for Parkinson's Disease (PD) and Alzheimer’s Disease (AD) using sleep-breathing data that is significantly more reliable, flexible, and economical than current diagnostic tools. His passive, in-home, contactless monitoring system—resembling a simple home Wi-Fi router—will also enable remote disease assessment and continuous progression tracking. Yuzhe’s work has the potential to advance the diagnosis and treatment of prevalent diseases like PD and AD, and offers exciting possibilities for addressing many health challenges with reliable, affordable machine-learning tools.
To view or add a comment, sign in
-
-
We were delighted to introduce InRAD, an international, practice-based registry for Alzheimer's Disease and other dementias at the EADC (European Alzheimer's Disease Consortium) annual meeting yesterday. One of our founding Board members, Frank Jessen, explained how InRAD can help address pressing questions about the clinical management of Alzheimer's disease, enable large study collaborations with a common minimum data set and facilitate a wide range of sub-studies on a global scale. Click here to find out more about InRAD and join our effort to accelerate progress in Alzheimer's practice-based research: https://lnkd.in/gGDTvs6i #InRAD #AlzheimersResearch #GlobalImpact #EADC #RealWorldData #AlzheimersRegistry
To view or add a comment, sign in
-
-
April is Parkinson's Awareness Month! 🤍 This special month aims to raise awareness on #ParkinsonsDisease and recognize its symptoms or early signs that can lead to an earlier diagnosis and overall better quality of life! Start learning more about Parkinson's Disease this month to spread the word and advance PD research. Check out our currently open Parkinson's clinical trials conducted by our Principal Investigators, Dr. Anna Morenkova and Dr. Nicolas Phielipp: https://bit.ly/3MDKIiG
To view or add a comment, sign in
-
-
How can a blood-based diagnostic test have the power to enhance clinical trials, and how can this support a new era of early intervention and hope for individuals affected by Alzheimer’s disease? Register for the webinar Thur Aug 24, 1 pm ET. https://lnkd.in/gHXSjrzp #alzheimersdisease #alzheimers #QuestPharmaSolutions #TestWithQuest #webinar #clinicaltrials
Register today! Discover how this blood-based diagnostic test has the power to enhance clinical trials, ushering in a new era of early intervention and hope for individuals affected by Alzheimer’s disease. During this webinar, Dr Michael Racke will explore the scientific basis of the blood-based diagnostic test, its reliability, and its potential impact as a less-invasive, more accessible tool that could transform the landscape of the disease. #alzheimersdisease #alzheimers #QuestPharmaSolutions #TestWithQuest https://lnkd.in/gHXSjrzp
To view or add a comment, sign in
-
-
Join us for this informative session with Quest clinical experts!
Register today! Discover how this blood-based diagnostic test has the power to enhance clinical trials, ushering in a new era of early intervention and hope for individuals affected by Alzheimer’s disease. During this webinar, Dr Michael Racke will explore the scientific basis of the blood-based diagnostic test, its reliability, and its potential impact as a less-invasive, more accessible tool that could transform the landscape of the disease. #alzheimersdisease #alzheimers #QuestPharmaSolutions #TestWithQuest https://lnkd.in/gHXSjrzp
To view or add a comment, sign in
-